Commercial Credit Report for Elicera Therapeutics AB

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Elicera Therapeutics AB is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Elicera Therapeutics AB
World Trade Center Goteborg
Massans gata 10, van 7
	GOETEBORG, 412 51 Sweden	Ticker: ELICELIC

Business Summary

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.

(Source: 10-K405)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
8731	Commercial physical and biological research

General Information

Number of Employees:	2	(As of 12/31/2023)
Outstanding Shares:	19,782,000	(As of 12/31/2023)
Stock Exchange:	STO

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN